Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus

Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus

Background: Type 2 diabetes mellitus (DM) is a risk factor for mycobacterial pulmonary infections (MPI), including tuberculosis (TB) and nontuberculous mycobacterial lung disease (NTM-LD). Dipeptidyl peptidase IV inhibitor (DPP4i), a common DM medication, has an immune-modulation effect that raises...

Full description

Bibliographic Details
Main Authors: Cheng-Yi Wang, Kuang-Ming Liao, Ya-Hui Wang, Kuang-Hung Chen, Shulin Chuang, Chia-Jung Liu, Chin-Chung Shu, Hao-Chien Wang
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:Journal of Infection and Public Health
Subjects:
Diabetes mellitus
Dipeptidyl peptidase IV inhibitors
Nontuberculous mycobacterial lung disease
Mycobacterial pulmonary infection
Tuberculosis
Online Access:http://www.sciencedirect.com/science/article/pii/S187603412300285X

Internet

http://www.sciencedirect.com/science/article/pii/S187603412300285X

Similar Items